CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers
Bitget2026/10/26 21:22- CERo Therapeutics activated UC Davis as a site for its ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
- UC Davis also manufactures CER-1236, potentially expanding recruitment capacity while shortening the time between manufacturing and patient infusion.
- Previously reported findings covered six patients; a June 2026 update showed no severe treatment-related adverse events during the initial safety assessment.
- Preliminary observations indicated clinical improvement in two patients, but formal assessments remain ongoing; definitive safety or efficacy conclusions cannot yet be drawn.
- The trial protocol now includes myelodysplastic syndromes and myelofibrosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
